Free Trial
NASDAQ:TXMD

TherapeuticsMD Q2 2023 Earnings Report

TherapeuticsMD logo
$1.10 +0.02 (+1.85%)
As of 02:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TherapeuticsMD EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.17
One Year Ago EPS
N/A

TherapeuticsMD Revenue Results

Actual Revenue
$0.44 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TherapeuticsMD Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Conference Call Date
Monday, August 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

TherapeuticsMD's Q2 2025 earnings is scheduled for Monday, August 11, 2025

TherapeuticsMD Earnings Headlines

The DOJ Just Paved the Way for Account Seizures
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

View TherapeuticsMD Profile

More Earnings Resources from MarketBeat